SlideShare uma empresa Scribd logo
1 de 18
Baixar para ler offline
“ANTIMICROBIALS 2020”
27 FEBRUARY 2020, MELBOURNE
Adrian Towse
Emeritus Director & Senior Research Fellow, OHE
Visiting Professor, London School of Economics
1. Acknowledgements
2. The role of HTA and contracting
3. HTA and contracting for antibiotics
4. What constitutes value for antibiotics?
5. Measuring and modelling antibiotic value
6. Innovative payment models
● UK proposals by NICE and NHS England
7. Conclusions and recommendations
● Options for Australia
8. References
27 FEBRUARY 2020
ANTIMICROBIALS 2020
27 FEBRUARY 2020
ANTIMICROBIALS 2020
Research funded by the
Wellcome Trust
Research with the
Academy of Infection
Management, funded by
GSK, MSD, and Roche
Research undertaken with AZ
and funded by AZ
The Office of Health Economics
is a not-for-profit (charity). It is
owned by the ABPI but operates
independently.
This trip is funded by MSD.
● The antibiotics available today are becoming obsolete at a fast pace, and industry development pipelines of antibiotics
are weak
● The development of antibiotics faces a threefold challenge:
● Scientific - due to the low success rates in R&D stages
● Regulatory and Clinical - due to the challenges of generating evidence of clinical superiority in randomised controlled
trial (RCT)
● Economic - due to the low expected returns on investments (ROI) from antibiotic sales
● A number of interventions have been proposed to antibiotics R&D:
● Push incentives - providing financial and scientific support the development of new antibiotics
● Pull incentives – providing rewards to manufacturers for bringing to market new antibiotics (e.g. market entry rewards,
volume-delinked payment models)
27 FEBRUARY 2020
ANTIMICROBIALS 2020
● Most national health systems undertake some form of value assessment of a new drug before providing or
reimbursing it for patients
● Value assessment of new drugs is typically based around evidence from randomised controlled trials (RCTs)
● Given the value assessment, health systems decide if the price charged by manufacturers is justified, or what price
they would be willing to pay, for all or some of the label indications of the new drug
● Manufacturers are generally then paid an agreed price per pill
● Deals may be struck on the ‘list’ price, taking account of expectations or limits on prescribing, of volume and
sometimes of outcomes
27 FEBRUARY 2020
ANTIMICROBIALS 2020
● Value assessment of new drugs is typically based around RCTs to show clinical superiority against a comparator
treatment. This is a problem for new antibiotics because:
● Estimates of effectiveness in patients to be treated are typically based on non-superiority trials
● Non-clinical data (such as PK/PD and in-vitro microbiological data) are typically not accepted by HTA agencies
● A considerable part of antibiotic value arises from externalities (benefits and costs to the non-treated individuals)
which are not measured in RCTs
● The treatment strategies which will maximise value to patients and the wider public are not considered in RCTs
● Most pricing & reimbursement arrangements agree a price per pill. This is a problem for new antibiotics because:
● Stewardship arrangements limit use of the drug during the period of patent protection to optimise long term social
value
● Low volumes will not provide a return on investment for developers
27 FEBRUARY 2020
-ANTIMICROBIALS 2020
● A considerable part of antibiotic value arises from ‘externalities (e.g. transmission of infections, impact on
rate of growth of AMR)
● Conventional HTA methods only include the effects associated with treating the immediate patient
● Examples of consideration in deliberative decision making, but no formal for AMR-related HTA
assessment (e.g. France)
● Recent legislation in Germany has established that AMR can be considered as an additional value element
of antibiotics, but not clear how this will be applied in practice
● Previous work by OHE (Karlsberg Schaffer et al., 2017) made the case for going beyond the benefits of
antibiotics typically considered in HTA (i.e. health gains and cost offsets, and in some systems also unmet
need, and productivity benefits) and identified public health benefits that are relevant to the health system
and wider society but are not considered in traditional assessments
27 FEBRUARY 2020
ANTIMICROBIALS 2020
WAY FORWARD: KEY POINTS
● The typically ‘not included’
elements of antibiotics appear to
be much larger than the immediate
health gain to the patient
● Research is needed to improve
value measurement approaches to
these, and avoid double counting
● Begin with the inclusion of the
value elements that have the
greatest impact on overall value,
and for which it is possible to
generate evidence of value
● Expert elicitation will be crucial to
get (i) agreement on strategy for
optimal use of a drug and (ii)
estimates to inform assessment of
‘not included’ elements of value.
27 FEBRUARY 2020
ANTIMICROBIALS 2020
Transmission value
Arises from preventing the spread of the
infection among the wider population by
treating individual patients
Enablement value
Arises, for example, from protecting the safety
of surgical procedures that rely on prophylactic
or post-operation antibiotics, or of using drugs
that suppress the immune system risking
infection
Diversity value
Arises from attenuating the ‘selection
pressure’ on existing antibiotics and
preserving the efficacy of these existing
treatments against resistant pathogens
Insurance value
Arises from having access to an effective
treatment available in case of a catastrophic
event, such as an outbreak of multi-drug
resistant pathogen
Novel action value
Arises from preventing cross-resistance
among classes of antibiotics, and fostering
R&D of ‘follow-on’ products with the same
mechanism of action
Spectrum value
Emerges from antibiotics that cover a narrower
spectrum of pathogens, preventing the
‘collateral damage’ to the microbiome and
reducing the build-up of AMR
Unmet need Productivity benefits
Health gains Cost offsets
TYPICALLY
INCLUDEDTYPICALLYNOTINCLUDED
● Proposals to model the value of the public health benefits of antibiotics in HTA using QALYs and
estimates of cost-effectiveness in:
● Morton et al. (forthcoming) - recommendations to modify incremental cost-effectiveness ratios
(ICERs) in order to capture the public health effects of antibiotics
● Rothery et al. (2018) - approach for a comprehensive assessment, including consideration of
relevant strategies for antibiotic use and estimation of population benefits using dynamic
models to simulate the dynamics of resistance transmission and development
27 FEBRUARY 2020
ANTIMICROBIALS 2020
REACTIONS & RECOMMENDATIONS
● Proposals rely on complex modelling exercises that require advanced expert capabilities for their implementation
● Adequate expert capacity may be available in some countries (e.g., UK and Australia), but progress is needed to build it
up in other countries
● Scarcity of data on AMR transmission and development
● Potential role of clinicians, epidemiologists and other expert judgement where data are missing or to simplify the
estimation of resistance trends and other key parameters
● Importance of using a perspective of analysis that captures appropriately the public health benefits of antibiotics
● Standard HTA methods rely on evidence from RCTs. These typically do not demonstrate clinical superiority of new
antibiotics, and are site based rather than pathogen based
● Appropriate antibiotic value should be modelled according to the clinically relevant strategies of use (typically
pathogen based) and to estimate of clinical value based on PK/PD data and expert opinion
● Some elements of antibiotic value (e.g. transmission value) are already applied to vaccines assessment
● The modelling expertise of certain member state agencies in charge of assessing vaccines (e.g. France, Germany and
England) could be used to assess the value of characteristics that are shared by vaccines and antibiotics
27 FEBRUARY 2020
ANTIMICROBIALS 2020
● The contracting of antibiotics is usually regulated through tariff-based payments (DRGs), which disincentivises the
optimal use of new antibiotics if their value is reflected in a high price
● US CMS NTAP process now reimburses 75% of price of a novel antibiotic outside of DRG, but this does not address
low volumes and need for stewardship
● Proposals from Duke-Margolis for antibiotic contracting in terms of models that delink payments from volume sold,
in order to provide appropriate R&D reward while promoting stewardship:
● Daniel et al. (2017) propose a Priority Antimicrobial Value Entry (PAVE) award, consisting of a pre-set
market entry reward available upon launch, and a progressive shift towards value-based contracts
● Schneider et al. (2020) propose a subscription model for the public sector (Medicare) patients
● Little discussion to date in Europe on novel contracting for antibiotics, it is unclear whether delinked payment
models will be considered because they represent a major departure from existing contracting approaches. Some
progress in:
● the UK - NICE and NHS England have recently announced a pilot programme of a delinked payment-based system
● Sweden - pilot of lump sum payment model, but this initiative seems to address the availability of antibiotics in the
Swedish market rather than providing appropriate R&D incentives
27 FEBRUARY 2020
ANTIMICROBIALS 2020
● Overall objective is to put in place a subscription model for purchasing antibiotics and ensure
that learnings are shared with the international community.
● Three elements
1. Selection of candidate drugs: Pilot of 2 drugs, one new and one existing, will be separate procurement lots,
use of procurement through “competitive dialogue”
2. Valuation: Use of modified NICE HTA processes with expert opinion to estimate range of ££ value; add to health
gain, cost savings, AMR specific elements of diversity; transmission; enablement; spectrum benefits; and
insurance benefits. Use of pre-clinical data (e.g. PK/PD data) to estimate health gain of the new drug.
3. Contracting: Expected to be fully delinked subscription model, with pre-agreed payments but linked to delivery of
data and of product when needed. Period not yet specified, but could be 5 years, renewable with new data.
● Timing: AMR 5 year vision launched January 2019, Pilot launched July 2019; Stakeholder update Nov 2019; draft
documents expected March 2020; selection by end 2020; valuations by end 2021; contracts negotiated in parallel,
expected end Q1 2022.
27 FEBRUARY 2020
ANTIMICROBIALS 2020
Governments should promote change in antibiotics assessment and contracting with internationally
coordinated initiatives. EUnetHTA for example, or successor bodies, could be tasked with a role in
developing a joint assessment of a new antibiotic, thus hopefully stimulating independent action.
Countries gaining experience with innovative HTA and contracting for
antibiotics should share the learnings with other countries to contribute to
the common understanding of the most effective policy interventions
27 FEBRUARY 2020
ANTIMICROBIALS 2020
Governments and funding institutions should continue to advocate
change to HTA and contracting for antibiotics around the world.
In the short-term, new antibiotics should be excluded from DRG-bundled payments to
disincentivise the use of cheaper drugs.
‘Volume-delinked’ payments represent a longer-term solution because these schemes
encourage better adherence to stewardship.
There is an overlap between the elements of value that are relevant for vaccines and antibiotics.
The advanced vaccines modelling approaches could be transferred to antibiotics to model the
patterns of transmission and herd immunity
Antibiotic value should be determined on consideration of actual
strategies of usage, even if these differ markedly from those tested in
registration trials
The elements of value that are most relevant for particular types of
antibiotics and usage scenarios should be identified and expert
elicitation should be used to inform modelling
27 FEBRUARY 2020
ANTIMICROBIALS 2020
● Like UK, Australia has high quality HTA valuation expertise for new vaccines and for new drugs
● Experience of “Netflix” style subscription model for Hep.C DAA drugs indicated to rest of the world Australia’s ability to
undertake innovative contracting arrangements
● Opportunity to introduce a subscription model along the broad lines of the UK approach of three elements:
● Selection process for candidates (UK planning 2 products initially)
● Valuation process – recognition that expert opinion will inform conventional HTA approaches, need for ad hoc
approaches whilst more detailed approaches are developed
● Contracting – multi-year “delinked” contract with obligation to supply in line with clinical protocols that enforce
appropriate stewardship of existing and new antibiotics
● Challenge of Federal versus State funding for hospital drugs. Comparable in some ways to UK challenge of decentralised
hospital contracts and NHS finances with a national subscription contract.
● The more experience the international community develops of contracting for new antibiotics, the sooner we will learn
how to get this right.
27 FEBRUARY 2020
ANTIMICROBIALS 2020
● Daniel et al. 2017. Value-based strategies for encouraging new development of antimicrobial drugs. Duke-Margolis Center
for Health Policy. Available at: https://healthpolicy.duke.edu/PAVE
● Dept of Health and Social Care. Jan 2019 Tackling antimicrobial resistance 2019 to 2024: the UK's 5-year national action
plan. Available at
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/784894/UK_AMR_5
_year_national_action_plan.pdf
● Dept of Health and Social Care.. Development of new antibiotics encouraged with new pharmaceutical payment system.
News story. July 2019. Available at https://www.gov.uk/government/news/development-of-new-antibiotics-encouraged-
with-new-pharmaceutical-payment-system
● Karlsberg Schaffer, S., West, P., Towse A., Henshall C., Mestre-Ferrandiz J., Masterton R., and Fischer, A. Assessing the
Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions. Office of Health
Economics Research Paper, May 2017Available at
https://www.ohe.org/system/files/private/publications/OHE%20AIM%20Assessing%20The%20Value%20of%20New%20
Antibiotics%20May%202017.pdf
● Neri, M., Hampson, G., Henshall, C. and Towse, A., 2019. HTA and payment mechanisms for new drugs to tackle AMR.
Available at https://www.ohe.org/publications/hta-and-payment-mechanisms-new-drugs-tackle-amr
27 FEBRUARY 2020
ANTIMICROBIALS 2020
● NICE and NHS England. Nov. 2019 Slide Deck for Stakeholders. Developing and testing innovative models for the
evaluation and purchase of antimicrobials. Available at http://amr.solutions/wp-content/uploads/99/2019-11-25_nhs-
nice_webinar_slides_-_draft_for_release.pdf
● Rothery et al. (2018). FRAMEWORK FOR VALUE ASSESSMENT OF NEW ANTIMICROBIALS. Implications of alternative
funding arrangements for NICE Appraisal. NIHR Policy Research Unit in Economic Evaluation of Health & Care
Interventions (EEPRU). Available at http://www.eepru.org.uk/wp-content/uploads/2017/11/eepru-report-amr-oct-2018-
059.pdf
● Schneider M. et al. February 17, 2020. Delinking US Antibiotic Payments through a Subscription Model in Medicare. Duke-
Margolis Center for Health Policy. Health Affairs blog. Available at:
https://www.healthaffairs.org/do/10.1377/hblog20200211.544900/full/
● Towse, A., Hoyle, C., Goodall, J., Hirsch, M., Mestre-Ferrandiz, J., Rex J. 2017. Time for a Change in How New Antibiotics
are Reimbursed: Development of an Insurance Framework for Funding New Antibiotics based on a Policy of Risk
Mitigation. Health Policy http://dx.doi.org/10.1016/j.healthpol.2017.07.011
27 FEBRUARY 2020
ANTIMICROBIALS 2020
To keep up with the latest news and research, subscribe to our blog.
OHE’s publications may be downloaded free of charge from our website.
OHE
Southside
105 Victoria Street
London SW1E 6QT
United Kingdom
Telephone
+44 (0)20 77478850
FOLLOW US
Toenquire about additional information and analyses,
please contact:
Adrian Towse
Director Emeritus and Senior Research Fellow
Visiting Professor London School of Economics
atowse@ohe.org

Mais conteúdo relacionado

Mais procurados

Multi-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKMulti-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKKerry Sheppard
 
Regulating for Innovation in England Sussex 2014
Regulating for Innovation in England Sussex 2014Regulating for Innovation in England Sussex 2014
Regulating for Innovation in England Sussex 2014Office of Health Economics
 
The Role of HTA for Biosimilars Mestre-Ferrandiz 2014
The Role of HTA for Biosimilars Mestre-Ferrandiz 2014The Role of HTA for Biosimilars Mestre-Ferrandiz 2014
The Role of HTA for Biosimilars Mestre-Ferrandiz 2014Office of Health Economics
 
The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...Francois MAIGNEN
 
Pharmacoeconomics & health policy
Pharmacoeconomics & health policyPharmacoeconomics & health policy
Pharmacoeconomics & health policyCepal & Co.
 
Mini-Course Starter Kits
Mini-Course Starter KitsMini-Course Starter Kits
Mini-Course Starter KitsEUPATI
 
Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing Office of Health Economics
 
Access to Orphan Drugs in the UK and Other European Countries
Access to Orphan Drugs in the UK and Other European CountriesAccess to Orphan Drugs in the UK and Other European Countries
Access to Orphan Drugs in the UK and Other European CountriesOffice of Health Economics
 
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Office of Health Economics
 
MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b
MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b
MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b Office of Health Economics
 
Oncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserOncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserPharmacy @ Institut Kanser Negara
 
Complex Innovative Trial Designs
Complex Innovative Trial DesignsComplex Innovative Trial Designs
Complex Innovative Trial DesignsFrancois MAIGNEN
 
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Office of Health Economics
 
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Bhaswat Chakraborty
 

Mais procurados (20)

HTA in France
HTA in FranceHTA in France
HTA in France
 
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UKMulti-Indication Pricing: Pros, Cons and Applicability to the UK
Multi-Indication Pricing: Pros, Cons and Applicability to the UK
 
Regulating for Innovation in England Sussex 2014
Regulating for Innovation in England Sussex 2014Regulating for Innovation in England Sussex 2014
Regulating for Innovation in England Sussex 2014
 
The Role of HTA for Biosimilars Mestre-Ferrandiz 2014
The Role of HTA for Biosimilars Mestre-Ferrandiz 2014The Role of HTA for Biosimilars Mestre-Ferrandiz 2014
The Role of HTA for Biosimilars Mestre-Ferrandiz 2014
 
Trends in Early Development
Trends in Early DevelopmentTrends in Early Development
Trends in Early Development
 
The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...The role of health technology assessment bodies in the value of cancer care i...
The role of health technology assessment bodies in the value of cancer care i...
 
Pharmacoeconomics & health policy
Pharmacoeconomics & health policyPharmacoeconomics & health policy
Pharmacoeconomics & health policy
 
Mini-Course Starter Kits
Mini-Course Starter KitsMini-Course Starter Kits
Mini-Course Starter Kits
 
Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing Making value-based pricing a reality – the case for multi-indication pricing
Making value-based pricing a reality – the case for multi-indication pricing
 
Access to Orphan Drugs in the UK and Other European Countries
Access to Orphan Drugs in the UK and Other European CountriesAccess to Orphan Drugs in the UK and Other European Countries
Access to Orphan Drugs in the UK and Other European Countries
 
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
 
Towards a Value Framework for Antibiotics
Towards a Value Framework for AntibioticsTowards a Value Framework for Antibiotics
Towards a Value Framework for Antibiotics
 
Pharmaconomics
PharmaconomicsPharmaconomics
Pharmaconomics
 
MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b
MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b
MCDA to elicit stakeholders' preferences in Italy. The Case of Obinutuzuma.b
 
Oncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserOncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End User
 
Complex Innovative Trial Designs
Complex Innovative Trial DesignsComplex Innovative Trial Designs
Complex Innovative Trial Designs
 
Managed Entry Agreements in Asia
Managed Entry Agreements in Asia Managed Entry Agreements in Asia
Managed Entry Agreements in Asia
 
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
Key factors driving access and uptake of hepatitis C treatments in Europe. Re...
 
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
 
HTA's 'Macro' Role in Health Care Systems
HTA's 'Macro' Role in Health Care SystemsHTA's 'Macro' Role in Health Care Systems
HTA's 'Macro' Role in Health Care Systems
 

Semelhante a Towse 2020 antimicrobials melbourne final

HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMROffice of Health Economics
 
How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?Office of Health Economics
 
The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMR
The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMRThe Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMR
The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMROffice of Health Economics
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...Office of Health Economics
 
Who antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipurWho antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipurAshish Gupta
 
CDC-core-elements.pdf
CDC-core-elements.pdfCDC-core-elements.pdf
CDC-core-elements.pdfssuser9f80d7
 
Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice cheweb1
 
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and                                          ...Principles of Pharmacoeconomics and                                          ...
Principles of Pharmacoeconomics and ...Aasritha William
 
Understanding the ABCs of and ASP
Understanding the ABCs of and ASPUnderstanding the ABCs of and ASP
Understanding the ABCs of and ASPCompleteRx
 
Revisiting Recommendations on Drug Resistance from Past Studies
Revisiting Recommendations on Drug Resistance from Past StudiesRevisiting Recommendations on Drug Resistance from Past Studies
Revisiting Recommendations on Drug Resistance from Past Studiescgdev
 
Introduction to budget impact analysis
Introduction to budget impact analysisIntroduction to budget impact analysis
Introduction to budget impact analysisNazmiLianaAzmi
 
Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)EuFMD
 
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...EuFMD
 
Stratified Medicines Innovation Platform
Stratified Medicines Innovation PlatformStratified Medicines Innovation Platform
Stratified Medicines Innovation PlatformEuroBioForum
 
Economic Incentives for New Antibiotics: What's Required?
Economic Incentives for New Antibiotics: What's Required?Economic Incentives for New Antibiotics: What's Required?
Economic Incentives for New Antibiotics: What's Required?Office of Health Economics
 
EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...EUPATI
 

Semelhante a Towse 2020 antimicrobials melbourne final (20)

HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
 
How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?How can we assess the value of new antibiotics?
How can we assess the value of new antibiotics?
 
The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMR
The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMRThe Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMR
The Role of HTA in Incentivising New Drugs and Vaccines to Tackle AMR
 
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingWebinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug Pricing
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
 
Who antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipurWho antibiotic policy iihmr jaipur
Who antibiotic policy iihmr jaipur
 
ABPI white paper
ABPI white paperABPI white paper
ABPI white paper
 
CDC-core-elements.pdf
CDC-core-elements.pdfCDC-core-elements.pdf
CDC-core-elements.pdf
 
Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice Evaluation of health technologies in France: from theory to practice
Evaluation of health technologies in France: from theory to practice
 
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and                                          ...Principles of Pharmacoeconomics and                                          ...
Principles of Pharmacoeconomics and ...
 
Understanding the ABCs of and ASP
Understanding the ABCs of and ASPUnderstanding the ABCs of and ASP
Understanding the ABCs of and ASP
 
Revisiting Recommendations on Drug Resistance from Past Studies
Revisiting Recommendations on Drug Resistance from Past StudiesRevisiting Recommendations on Drug Resistance from Past Studies
Revisiting Recommendations on Drug Resistance from Past Studies
 
ADAPTIVE PATHWAYS
ADAPTIVE PATHWAYSADAPTIVE PATHWAYS
ADAPTIVE PATHWAYS
 
Introduction to budget impact analysis
Introduction to budget impact analysisIntroduction to budget impact analysis
Introduction to budget impact analysis
 
Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)
 
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
 
Infection control in modern hospitals
Infection control in modern hospitalsInfection control in modern hospitals
Infection control in modern hospitals
 
Stratified Medicines Innovation Platform
Stratified Medicines Innovation PlatformStratified Medicines Innovation Platform
Stratified Medicines Innovation Platform
 
Economic Incentives for New Antibiotics: What's Required?
Economic Incentives for New Antibiotics: What's Required?Economic Incentives for New Antibiotics: What's Required?
Economic Incentives for New Antibiotics: What's Required?
 
EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...EUPATI guidances for interaction between Patient organisations and other stak...
EUPATI guidances for interaction between Patient organisations and other stak...
 

Mais de Office of Health Economics

Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowseOffice of Health Economics
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isOffice of Health Economics
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?Office of Health Economics
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeOffice of Health Economics
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandOffice of Health Economics
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Office of Health Economics
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
 
Lies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source ModelsLies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source ModelsOffice of Health Economics
 
THE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARE
THE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARETHE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARE
THE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CAREOffice of Health Economics
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 

Mais de Office of Health Economics (20)

Annual lecture
Annual lecture Annual lecture
Annual lecture
 
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
 
Lies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source ModelsLies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source Models
 
THE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARE
THE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARETHE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARE
THE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARE
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 

Último

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 

Último (20)

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 

Towse 2020 antimicrobials melbourne final

  • 1. “ANTIMICROBIALS 2020” 27 FEBRUARY 2020, MELBOURNE Adrian Towse Emeritus Director & Senior Research Fellow, OHE Visiting Professor, London School of Economics
  • 2. 1. Acknowledgements 2. The role of HTA and contracting 3. HTA and contracting for antibiotics 4. What constitutes value for antibiotics? 5. Measuring and modelling antibiotic value 6. Innovative payment models ● UK proposals by NICE and NHS England 7. Conclusions and recommendations ● Options for Australia 8. References 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 3. 27 FEBRUARY 2020 ANTIMICROBIALS 2020 Research funded by the Wellcome Trust Research with the Academy of Infection Management, funded by GSK, MSD, and Roche Research undertaken with AZ and funded by AZ The Office of Health Economics is a not-for-profit (charity). It is owned by the ABPI but operates independently. This trip is funded by MSD.
  • 4. ● The antibiotics available today are becoming obsolete at a fast pace, and industry development pipelines of antibiotics are weak ● The development of antibiotics faces a threefold challenge: ● Scientific - due to the low success rates in R&D stages ● Regulatory and Clinical - due to the challenges of generating evidence of clinical superiority in randomised controlled trial (RCT) ● Economic - due to the low expected returns on investments (ROI) from antibiotic sales ● A number of interventions have been proposed to antibiotics R&D: ● Push incentives - providing financial and scientific support the development of new antibiotics ● Pull incentives – providing rewards to manufacturers for bringing to market new antibiotics (e.g. market entry rewards, volume-delinked payment models) 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 5. ● Most national health systems undertake some form of value assessment of a new drug before providing or reimbursing it for patients ● Value assessment of new drugs is typically based around evidence from randomised controlled trials (RCTs) ● Given the value assessment, health systems decide if the price charged by manufacturers is justified, or what price they would be willing to pay, for all or some of the label indications of the new drug ● Manufacturers are generally then paid an agreed price per pill ● Deals may be struck on the ‘list’ price, taking account of expectations or limits on prescribing, of volume and sometimes of outcomes 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 6. ● Value assessment of new drugs is typically based around RCTs to show clinical superiority against a comparator treatment. This is a problem for new antibiotics because: ● Estimates of effectiveness in patients to be treated are typically based on non-superiority trials ● Non-clinical data (such as PK/PD and in-vitro microbiological data) are typically not accepted by HTA agencies ● A considerable part of antibiotic value arises from externalities (benefits and costs to the non-treated individuals) which are not measured in RCTs ● The treatment strategies which will maximise value to patients and the wider public are not considered in RCTs ● Most pricing & reimbursement arrangements agree a price per pill. This is a problem for new antibiotics because: ● Stewardship arrangements limit use of the drug during the period of patent protection to optimise long term social value ● Low volumes will not provide a return on investment for developers 27 FEBRUARY 2020 -ANTIMICROBIALS 2020
  • 7. ● A considerable part of antibiotic value arises from ‘externalities (e.g. transmission of infections, impact on rate of growth of AMR) ● Conventional HTA methods only include the effects associated with treating the immediate patient ● Examples of consideration in deliberative decision making, but no formal for AMR-related HTA assessment (e.g. France) ● Recent legislation in Germany has established that AMR can be considered as an additional value element of antibiotics, but not clear how this will be applied in practice ● Previous work by OHE (Karlsberg Schaffer et al., 2017) made the case for going beyond the benefits of antibiotics typically considered in HTA (i.e. health gains and cost offsets, and in some systems also unmet need, and productivity benefits) and identified public health benefits that are relevant to the health system and wider society but are not considered in traditional assessments 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 8. WAY FORWARD: KEY POINTS ● The typically ‘not included’ elements of antibiotics appear to be much larger than the immediate health gain to the patient ● Research is needed to improve value measurement approaches to these, and avoid double counting ● Begin with the inclusion of the value elements that have the greatest impact on overall value, and for which it is possible to generate evidence of value ● Expert elicitation will be crucial to get (i) agreement on strategy for optimal use of a drug and (ii) estimates to inform assessment of ‘not included’ elements of value. 27 FEBRUARY 2020 ANTIMICROBIALS 2020 Transmission value Arises from preventing the spread of the infection among the wider population by treating individual patients Enablement value Arises, for example, from protecting the safety of surgical procedures that rely on prophylactic or post-operation antibiotics, or of using drugs that suppress the immune system risking infection Diversity value Arises from attenuating the ‘selection pressure’ on existing antibiotics and preserving the efficacy of these existing treatments against resistant pathogens Insurance value Arises from having access to an effective treatment available in case of a catastrophic event, such as an outbreak of multi-drug resistant pathogen Novel action value Arises from preventing cross-resistance among classes of antibiotics, and fostering R&D of ‘follow-on’ products with the same mechanism of action Spectrum value Emerges from antibiotics that cover a narrower spectrum of pathogens, preventing the ‘collateral damage’ to the microbiome and reducing the build-up of AMR Unmet need Productivity benefits Health gains Cost offsets TYPICALLY INCLUDEDTYPICALLYNOTINCLUDED
  • 9. ● Proposals to model the value of the public health benefits of antibiotics in HTA using QALYs and estimates of cost-effectiveness in: ● Morton et al. (forthcoming) - recommendations to modify incremental cost-effectiveness ratios (ICERs) in order to capture the public health effects of antibiotics ● Rothery et al. (2018) - approach for a comprehensive assessment, including consideration of relevant strategies for antibiotic use and estimation of population benefits using dynamic models to simulate the dynamics of resistance transmission and development 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 10. REACTIONS & RECOMMENDATIONS ● Proposals rely on complex modelling exercises that require advanced expert capabilities for their implementation ● Adequate expert capacity may be available in some countries (e.g., UK and Australia), but progress is needed to build it up in other countries ● Scarcity of data on AMR transmission and development ● Potential role of clinicians, epidemiologists and other expert judgement where data are missing or to simplify the estimation of resistance trends and other key parameters ● Importance of using a perspective of analysis that captures appropriately the public health benefits of antibiotics ● Standard HTA methods rely on evidence from RCTs. These typically do not demonstrate clinical superiority of new antibiotics, and are site based rather than pathogen based ● Appropriate antibiotic value should be modelled according to the clinically relevant strategies of use (typically pathogen based) and to estimate of clinical value based on PK/PD data and expert opinion ● Some elements of antibiotic value (e.g. transmission value) are already applied to vaccines assessment ● The modelling expertise of certain member state agencies in charge of assessing vaccines (e.g. France, Germany and England) could be used to assess the value of characteristics that are shared by vaccines and antibiotics 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 11. ● The contracting of antibiotics is usually regulated through tariff-based payments (DRGs), which disincentivises the optimal use of new antibiotics if their value is reflected in a high price ● US CMS NTAP process now reimburses 75% of price of a novel antibiotic outside of DRG, but this does not address low volumes and need for stewardship ● Proposals from Duke-Margolis for antibiotic contracting in terms of models that delink payments from volume sold, in order to provide appropriate R&D reward while promoting stewardship: ● Daniel et al. (2017) propose a Priority Antimicrobial Value Entry (PAVE) award, consisting of a pre-set market entry reward available upon launch, and a progressive shift towards value-based contracts ● Schneider et al. (2020) propose a subscription model for the public sector (Medicare) patients ● Little discussion to date in Europe on novel contracting for antibiotics, it is unclear whether delinked payment models will be considered because they represent a major departure from existing contracting approaches. Some progress in: ● the UK - NICE and NHS England have recently announced a pilot programme of a delinked payment-based system ● Sweden - pilot of lump sum payment model, but this initiative seems to address the availability of antibiotics in the Swedish market rather than providing appropriate R&D incentives 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 12. ● Overall objective is to put in place a subscription model for purchasing antibiotics and ensure that learnings are shared with the international community. ● Three elements 1. Selection of candidate drugs: Pilot of 2 drugs, one new and one existing, will be separate procurement lots, use of procurement through “competitive dialogue” 2. Valuation: Use of modified NICE HTA processes with expert opinion to estimate range of ££ value; add to health gain, cost savings, AMR specific elements of diversity; transmission; enablement; spectrum benefits; and insurance benefits. Use of pre-clinical data (e.g. PK/PD data) to estimate health gain of the new drug. 3. Contracting: Expected to be fully delinked subscription model, with pre-agreed payments but linked to delivery of data and of product when needed. Period not yet specified, but could be 5 years, renewable with new data. ● Timing: AMR 5 year vision launched January 2019, Pilot launched July 2019; Stakeholder update Nov 2019; draft documents expected March 2020; selection by end 2020; valuations by end 2021; contracts negotiated in parallel, expected end Q1 2022. 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 13. Governments should promote change in antibiotics assessment and contracting with internationally coordinated initiatives. EUnetHTA for example, or successor bodies, could be tasked with a role in developing a joint assessment of a new antibiotic, thus hopefully stimulating independent action. Countries gaining experience with innovative HTA and contracting for antibiotics should share the learnings with other countries to contribute to the common understanding of the most effective policy interventions 27 FEBRUARY 2020 ANTIMICROBIALS 2020 Governments and funding institutions should continue to advocate change to HTA and contracting for antibiotics around the world.
  • 14. In the short-term, new antibiotics should be excluded from DRG-bundled payments to disincentivise the use of cheaper drugs. ‘Volume-delinked’ payments represent a longer-term solution because these schemes encourage better adherence to stewardship. There is an overlap between the elements of value that are relevant for vaccines and antibiotics. The advanced vaccines modelling approaches could be transferred to antibiotics to model the patterns of transmission and herd immunity Antibiotic value should be determined on consideration of actual strategies of usage, even if these differ markedly from those tested in registration trials The elements of value that are most relevant for particular types of antibiotics and usage scenarios should be identified and expert elicitation should be used to inform modelling 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 15. ● Like UK, Australia has high quality HTA valuation expertise for new vaccines and for new drugs ● Experience of “Netflix” style subscription model for Hep.C DAA drugs indicated to rest of the world Australia’s ability to undertake innovative contracting arrangements ● Opportunity to introduce a subscription model along the broad lines of the UK approach of three elements: ● Selection process for candidates (UK planning 2 products initially) ● Valuation process – recognition that expert opinion will inform conventional HTA approaches, need for ad hoc approaches whilst more detailed approaches are developed ● Contracting – multi-year “delinked” contract with obligation to supply in line with clinical protocols that enforce appropriate stewardship of existing and new antibiotics ● Challenge of Federal versus State funding for hospital drugs. Comparable in some ways to UK challenge of decentralised hospital contracts and NHS finances with a national subscription contract. ● The more experience the international community develops of contracting for new antibiotics, the sooner we will learn how to get this right. 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 16. ● Daniel et al. 2017. Value-based strategies for encouraging new development of antimicrobial drugs. Duke-Margolis Center for Health Policy. Available at: https://healthpolicy.duke.edu/PAVE ● Dept of Health and Social Care. Jan 2019 Tackling antimicrobial resistance 2019 to 2024: the UK's 5-year national action plan. Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/784894/UK_AMR_5 _year_national_action_plan.pdf ● Dept of Health and Social Care.. Development of new antibiotics encouraged with new pharmaceutical payment system. News story. July 2019. Available at https://www.gov.uk/government/news/development-of-new-antibiotics-encouraged- with-new-pharmaceutical-payment-system ● Karlsberg Schaffer, S., West, P., Towse A., Henshall C., Mestre-Ferrandiz J., Masterton R., and Fischer, A. Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions. Office of Health Economics Research Paper, May 2017Available at https://www.ohe.org/system/files/private/publications/OHE%20AIM%20Assessing%20The%20Value%20of%20New%20 Antibiotics%20May%202017.pdf ● Neri, M., Hampson, G., Henshall, C. and Towse, A., 2019. HTA and payment mechanisms for new drugs to tackle AMR. Available at https://www.ohe.org/publications/hta-and-payment-mechanisms-new-drugs-tackle-amr 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 17. ● NICE and NHS England. Nov. 2019 Slide Deck for Stakeholders. Developing and testing innovative models for the evaluation and purchase of antimicrobials. Available at http://amr.solutions/wp-content/uploads/99/2019-11-25_nhs- nice_webinar_slides_-_draft_for_release.pdf ● Rothery et al. (2018). FRAMEWORK FOR VALUE ASSESSMENT OF NEW ANTIMICROBIALS. Implications of alternative funding arrangements for NICE Appraisal. NIHR Policy Research Unit in Economic Evaluation of Health & Care Interventions (EEPRU). Available at http://www.eepru.org.uk/wp-content/uploads/2017/11/eepru-report-amr-oct-2018- 059.pdf ● Schneider M. et al. February 17, 2020. Delinking US Antibiotic Payments through a Subscription Model in Medicare. Duke- Margolis Center for Health Policy. Health Affairs blog. Available at: https://www.healthaffairs.org/do/10.1377/hblog20200211.544900/full/ ● Towse, A., Hoyle, C., Goodall, J., Hirsch, M., Mestre-Ferrandiz, J., Rex J. 2017. Time for a Change in How New Antibiotics are Reimbursed: Development of an Insurance Framework for Funding New Antibiotics based on a Policy of Risk Mitigation. Health Policy http://dx.doi.org/10.1016/j.healthpol.2017.07.011 27 FEBRUARY 2020 ANTIMICROBIALS 2020
  • 18. To keep up with the latest news and research, subscribe to our blog. OHE’s publications may be downloaded free of charge from our website. OHE Southside 105 Victoria Street London SW1E 6QT United Kingdom Telephone +44 (0)20 77478850 FOLLOW US Toenquire about additional information and analyses, please contact: Adrian Towse Director Emeritus and Senior Research Fellow Visiting Professor London School of Economics atowse@ohe.org